RedHill Biopharma (NASDAQ:RDHL) Stock Passes Below Two Hundred Day Moving Average of $1.51
RedHill Biopharma (NASDAQ:RDHL) Stock Passes Below Two Hundred Day Moving Average of $1.51
RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating)'s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.51 and traded as low as $0.94. RedHill Biopharma shares last traded at $1.02, with a volume of 1,519,624 shares traded.
纳斯达克周三交易中，红山生物的股价跌破200日移动均线，200日移动均线切入位为1.51美元，最低交易价格为0.94美元。红山生物的股票最新报1.02美元，成交量为1,519,624股。
RedHill Biopharma Price Performance
红山生物医药的价格表现
The company's 50 day moving average is $0.91 and its 200 day moving average is $1.51. The company has a current ratio of 0.98, a quick ratio of 0.79 and a debt-to-equity ratio of 9.42. The stock has a market capitalization of $53.74 million, a price-to-earnings ratio of -0.54 and a beta of 1.86.
该公司的50日移动均线切入位在0.91美元，200日移动均线切入位在1.51美元。该公司的流动比率为0.98，速动比率为0.79，债务权益比率为9.42。该股市值为5,374万美元，市盈率为-0.54倍，贝塔系数为1.86。
RedHill Biopharma (NASDAQ:RDHL – Get Rating) last announced its quarterly earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative net margin of 110.31% and a negative return on equity of 822.29%. The firm had revenue of $18.24 million for the quarter. During the same quarter in the prior year, the business earned ($0.53) earnings per share. Research analysts anticipate that RedHill Biopharma Ltd. will post -0.95 EPS for the current fiscal year.
红山生物科技(纳斯达克代码：RDHL-GET Rating)上一次公布季度收益是在6月23日星期四。这家生物技术公司公布了本季度每股收益(0.30美元)，比普遍预期的(0.40美元)高出0.10美元。红山生物医药的净利润率为负110.31%，净资产回报率为负822.29%。该公司本季度的收入为1824万美元。在去年同一季度，该业务实现了每股收益(0.53美元)。研究分析师预计，红山生物制药有限公司本财年的每股收益将达到0.95美元。
Institutional Inflows and Outflows
机构资金流入和流出
About RedHill Biopharma
关于雷德希尔生物医药公司
(Get Rating)
(获取评级)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
红山生物制药有限公司是一家专业的生物制药公司，主要专注于胃肠道和传染病。该公司推广胃肠药物，包括用于治疗患有慢性非癌症疼痛的成人阿片类药物引起的便秘的Movantik；用于治疗成人幽门螺杆菌感染的Talicia；以及用于治疗成人旅行者腹泻的Aemcolo。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- PENN Entertainment Stock is Reset and Ready to Rebound
- 3 Payroll Software Makers Set For Growth In 2023
- NYSE Stocks Give Investors a Variety of Quality Options
- Zoom Video Communications Valuation Is Realigned With Reality
- The J.M. Smucker Company Proves Why Staples Are Outperforming
- 免费获取StockNews.com关于RedHill Biophma(RDHL)的研究报告
- 宾夕法尼亚娱乐公司股票重置，准备反弹
- 3家薪资软件制造商将在2023年实现增长
- 纽约证交所股票为投资者提供多种优质选择
- ZOOM视频通信估值与现实重新接轨
- J.M.斯莫克公司证明了史泰博表现优异的原因
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《红山生物报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对RedHill Biophma和相关公司的最新新闻和分析师评级的每日简要摘要。